Menu

1 / 47

Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies - Eli Lilly (NYSE:LLY)

Top Stories Feed·Vandana Singh·2 days ago
#FRCsQ6nG
#benzinga#lilly#stipple#cancer#develop
Reading 0:00
15s threshold

Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies

Vandana SinghBenzinga Staff Writer November 17, 2026, 12:18 PM ETNov 17, 12:18 PM ET3 min read3 min

LLYEli Lilly and Co

$1410.72-1.46%

Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Monday to develop targeted cancer therapies.

The agreement covers multiple drug targets and therapeutic approaches, with Stipple Bio eligible to receive up to $5.9 billion in milestone payments, along with royalties on potential product sales.

Deal Terms

Under the agreement, Stipple Bio will receive an upfront payment and an equity investment from Eli Lilly.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.